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Abstract
Background
Magnetic Resonance Imaging (MRI) techniques provided evidences into the understanding
of cognitive impairment (CIm) in Multiple Sclerosis (MS).
Objectives
To investigate the role of white matter (WM) and gray matter (GM) in predicting long-term
CIm in a cohort of MS patients.
Methods
303 out of 597 patients participating in a previous multicenter clinical-MRI study were en-
rolled (49.4% were lost at follow-up). The following MRI parameters, expressed as fraction
(f) of intracranial volume, were evaluated: cerebrospinal fluid (CSF-f), WM-f, GM-f and ab-
normal WM (AWM-f), a measure of lesion load. Nine years later, cognitive status was as-
sessed in 241 patients using the Symbol Digit Modalities Test (SDMT), the Semantically
Related Word List Test (SRWL), the Modified Card Sorting Test (MCST), and the Paced Au-
ditory Serial Addition Test (PASAT). In particular, being SRWL a memory test, both immedi-
ate recall and delayed recall were evaluated. MCST scoring was calculated based on the
number of categories, number of perseverative and non-perseverative errors.
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Results
AWM-f was predictive of an impaired performance 9 years ahead in SDMT (OR 1.49, CI
1.12–1.97 p = 0.006), PASAT (OR 1.43, CI 1.14–1.80 p = 0.002), SRWL-immediate recall
(OR 1.72 CI 1.35–2.20 p<0.001), SRWL-delayed recall (OR 1.61 CI 1.28–2.03 p<0.001),
MCST-category (OR 1.52, CI 1.2–1.9 p<0.001), MCST-perseverative error(OR 1.51 CI
1.2–1.9 p = 0.001), MCST-non perseverative error (OR 1.26 CI 1.02–1.55 p = 0.032).
Conclusion
In our large MS cohort, focal WM damage appeared to be the most relevant predictor of the
long-term cognitive outcome.
Introduction
Cognitive Impairment (CIm) has been recognized as an important feature of Multiple Sclerosis
(MS), affecting up to 65% patients. CIm, such as memory impairment, reduced information
processing speed, attention deficit, impaired executive function, can occur from the early stage
of the disease and tends to worsen over time. The prevailing pattern of CIm in MS is repre-
sented by attention, processing speed, memory, executive function and visuo-spatial deficits,
while language abilities are typically unaffected [1]. In the last years, novel Magnetic Resonance
Imaging (MRI) techniques have provided further evidences into the understanding of CIm in
MS, highlighting the involvement of both white matter (WM) and gray matter (GM) damage
in the development of disability [2, 3].T1-, T2-lesion load (LL) and brain atrophy measures
may predict the onset of CIm after several years [4, 5]. Conversely, other studies showed a clear
discrepancy between LL and severity of CIm in MS [6].WM abnormalities were weakly corre-
lated with CIm, suggesting that WM abnormalities alone cannot fully explain the extent of clin-
ical symptoms and CIm in MS [7, 8].In the present study, WM, and GM atrophy andWM LL
were obtained through a fully automated, operator-independent, multiparametric segmenta-
tion method from a large MS population [9, 10]. By using this approach, we recently showed
that baseline (BL) GM atrophy and EDSS were the best long-term (9 years follow-up) predic-
tors of clinical disease progression in relapsing remitting (RR) MS patients[11].Considering
these findings, the aim of the present study was to investigate the role of WM and GM damage
in predicting long term (9 years follow-up) CIm in a large multicenter cohort of MS patients.
Materials and Methods
Ethics statement
The study was previously approved by the Ethics Committee (EC) of the Second University of
Naples and then by all local EC of each participating center: EC “Federico II”Naples, EC Uni-
versity Hospital Policlinico Palermo, EC University Hospital Policlinico Catanzaro, EC Univer-
sity Hospital Policlinico Messina, EC University Hospital Policlinico Bari, National Research
Council, Naples. A written informed consent was obtained from every patient before
study initiation.
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Patients
In line with our recent paper, of the initial cohort of 597 MS patients participating to the previous
multicenter clinical/MRI research, 303 subjects were enrolled in this 9-year follow-up (FU) study
(49.4% lost at FU). The reasons for drop-out were: missing contact information (50.7%), unavail-
ability (24.1%), refusal (20.1%), death (3.4%), and other major medical illnesses (1.7%). There
were no significant differences in BL demographic or clinical data between patients lost at FU
and those participating in the initial cross-sectional study, except for a minor percentage of RR
patients in the dropped-out population (65% RR patients in the dropped out group, 72.4% in the
FU group; p<0.02) [11]. Out of 303 subjects, 241 underwent the Neuropsychological (NPS) bat-
tery. Furthermore, not all patients performed the whole NPS battery; a slight partial incomplete-
ness was obtained for some test because of the challenging duration of the NPS examination. At
BL and at FU, disability was measured by the EDSS and fatigue was evaluated by the Fatigue Se-
verity Scale (FSS). ΔEDSS and ΔFSS represent the variation of these parameters during FU. Nine
years after, 42 out of 241(17.4%) RRMS patients converted to Secondary-Progressive (SP) MS
(RR! SP), while the remaining 199 (82.6%) did not change their disease phenotype (RR! RR).
MRI imaging
At BL, the enrolled patients underwent the MRI protocol described in the previous cross-sec-
tional study [10]. In brief, conventional spin echo sequences were acquired to obtain
T1-weighted (TR/TE 600/15 msec, two averages) and dual echo (TR/TE2300/15–90 msec, one
average) images, with 90°flip angle and 256 × 192 matrix size. All the studies were segmented
using a multispectral, fully automated method, based on relaxometric characterization of brain
tissues [9]. The program furnishes complete sets of multifeature images [R1 (= 1/T1), R2 (= 1/
T2), proton density (N(H))-based] and segmented images of the following intracranial tissues:
cerebrospinal fluid (CSF), WM, GM, abnormal WM. AWM is a WM LL measure as deter-
mined by the R1, R2, and N(H) information and morphological characteristics. The relaxo-
metric method used provides GM segmentation not influenced by WM lesions [12]. For each
study, a couple of interactive interslice movies of both multifeature and segmented images
were produced, and two neuroimaging experts reviewed them (for a maximum of 2 minutes)
to detect motion artifacts and segmentation errors due to the imperfect separation of nasal mu-
cosa and vitreous humor from brain tissue. To normalize for head size variability, the volumes
were expressed as fraction (f) of intracranial volume. AWM-f is measure of LL. The reduction
of WM-f and GM-f indicate respectively WM and GM volume reduction. The increase of CSF-
f indicates global brain volume reduction. Fig. 1 shows a transverse slice of a patient with MS
and depicts the major steps of the multiparametric method.
Neuropsychological evaluation (NPS)
At the 9-year FU visit, all patients underwent the same NPS battery, standardized among the
participating centers. Tests were administered during daytime, in a quiet room. A brief neuro-
psychological battery was administered to explore the following cognitive domains.
Sustained attention. Symbol Digit Modalities Test (SDMT, number of correct pairings).
Patients are presented a series of nine symbols. Every symbol is paired with a single digit, labeled
1–9. In the test page a pseudo-randomized sequence of symbols is presented. Patients have to
write the correct digit associated to every symbols as quick as possible in 90 seconds [13]
Verbal memory. Semantically related word list test (SRWL):the test consisted of five con-
secutive immediate free-recall trials (I-R), followed by a 15-min delayed recall trial (D-R) and
recognition of 16 words from 4 categories: animals, transportation, vegetables and furniture
[14].
Cognitive Dysfunction and Multiple Sclerosis
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Executive functions, conceptual reasoning. Modified Card Sorting Test (MCST) was
adapted to improve Wisconsin Card Sort Test (WCST), simplifying the task, removing the am-
biguity in interpreting responses and providing measure of perseveration. The cards were
Fig 1. Axial image of a Multiple Sclerosis patient. (A) Proton density-weighted image; (B) T2-weighted image; (C) corresponding multiparametric image;
(D) segmented image. In the segmented image, white matter is represented by white, gray matter by gray, cerebrospinal fluid by blue, and lesions by yellow.
doi:10.1371/journal.pone.0120754.g001
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always presented to each participant in the same order according to the sequence provided by
the numbers at the back of the cards. Errors were scored as perseverative if the sorting response
was the same category (color, form, number) as the previously incorrect response, or if the sort-
ing response did not change after the patient was told that the rules had changed. An error was
scored as not perseverative if the patient followed a sorting response to neither color, form or
number (“other” response) with a second “other” response. MCST scoring is based on the
number of categories completed and the number of perseverative and non-perseverative errors
[15].
Information speed processing, working memory. Three-second version of Paced Audi-
tory Serial Addition Test (PASAT) is a test measuring sustained attention and information pro-
cessing speed. This test is included in the Brief Repeatable Battery of Neuropsychological test
(BRB). A series of single digit numbers from a type record are presented to the subject at the
rate of one every 3 seconds. The subject is asked to add every digit to the one immediately pro-
ceeding. The test is composed by 61 digits, the maximum score is 60 [16].
PASAT and SDMT were corrected using the available normative data for the Italian popula-
tion. We considered as cut off point a corrected score below the 5th percentile of the normative
data [17]. SRWL raw scores were corrected for sex, age and education; cut-off points were cal-
culated using the available normative data [14]. MCST raw scores were corrected for age; a cut
off was calculated for every measure using the available internal tolerance limit according to
the MCST-Roma version [18].
Higher values indicate better performances in all tests but MCST perseverative and non per-
severative error; in these items higher values indicate worse performance. An overall Cognitive
Index (CI) grading score was calculated for each patient. Considering the number of standard
deviations (SD) below mean of normative values, cognitive tests were graded as follows:0, at or
above mean value; 1, below mean but at or above 1 SD below mean; 2,< 1SD below mean but
at or above 2SD below mean; 3,<2SD below mean but at or above 3SD below mean; 4,<3SD
below mean. These grades were summed to obtain an overall CIm for each patient [19]. CIm
was defined as the failure on at least two tests involving at least two different domain (verbal
memory, attention/information processing speed and executive functions).
Statistical Analysis
Age, disease duration, NPS scores and MRI volume data are presented as means and SD (see
Table 1). Individual variables were checked for skewness and presence of outliers and the mean
MRI parameters of all subjects were adjusted for age, gender and education using a linear re-
gression model. Statistical analysis was performed using STATA 12.0, and a p value< 0.05 was
considered statistically significant. Chi square test was used to compare NPS test score and
CIm between RR! RR and RR!SP.
Several univariable logistic regression were fit considering binomial “impaired yes/no” vari-
able for each NPS as dependent and age, age at onset, CSF-f, AWM-f, GM-f, GWM-f, WM-f,
BLEDSS, ΔEDSS, BLFSS, ΔFSS, disease duration, progression to SPMS and gender as indepen-
dent variables. Variables correlating with outcomes (p< 0.1) in univariable analysis were used
as independent variables in logistic stepwise regression, considering p = 0.10 as the critical
value for entering or excluding variables in the model. A negative binomial regression analysis
was performed to evaluate the correlation with the severity of CIm index score.
Results
Demographic, clinical, cognitive and MRI data are summarized in Table 1. In Tables 2 and 3
univariable and multivariable analyses are summarized. SDMT scores of 222 MS patients were
Cognitive Dysfunction and Multiple Sclerosis
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evaluated. Nineteen patients were excluded from the analysis because their SDMT scores were
not available. If compared to the RR!SP, RR!RR group showed higher SDMT scores
(p<0.001). The logistic regression step-wise model regarding SDMT showed a significant posi-
tive correlation with AWM-f (OR 1.49, CI 1.12–1.97 p = 0.006), EDSS at BL (OR 1.066 CI
1.19–2.32 p = 0.003), ΔEDSS (OR 1.66 CI 1.19–2.32 p = 0.003), ΔFSS (OR1.66 CI 1.4–2.2
p<0.001). This means that for a 1% increase in AWM-f there was a 49% increased odds to be
cognitively impaired at this test. Moreover, the EDSS at BL and the variations in EDSS and FSS
scores were related to higher impaired scores at SDMT (see Table 3).
PASAT scores of 217 MS patients were evaluated. Twenty-four patients were excluded from
the analysis because their PASAT scores were not available. Seventy-three percent of RR!SP
and 43% of RR!RR patients’ scores were under cutoff (p = 0.002). PASAT showed a positive
correlation with AWM-f (OR 1.43, CI 1.14–1.80 p = 0.002) and age (OR 1.04, CI 1.01–1.08
p = 0.004). In other words, for a 1% increase of AWM-f there was a 43% increased odds of hav-
ing impaired PASAT scores. One year increase in age was related to 4% increased odds of im-
paired score at this test (see Table 3).
SRWL scores of 230 MS patients were evaluated. Eleven patients were excluded from the
analysis because their SRWL scores were not available. Thirty-three per cent of RR!SP pa-
tients and 12% of RR!RR patients showed SRWL-immediate recall (IR) under cut off
(p = 0.001). SRWL-IR score showed a positive correlation with AWM-f (OR 1.72 CI 1.35–2.20
p<0.001) and ΔFSS (OR 1.04 CI 1.01–1.06 p = 0.006) such that a 1% increase of AWM-f was
related to 72% higher odds to be impaired at this test. ΔFSS was related to higher odds of im-
paired performances at this test. The SRWL-delayed recall (DR) was statistically different be-
tween 2 groups, with 30% RR!SP patients showing SRWL scores under cut off if compared to
Table 1. Demographic, clinical characteristics, *adjusted baseline MRI volume (as percentage of
whole brain volume) and **neuropsychological test scores of MS patients (mean ± SD).
RR-RR RR-SP
n n = 199 n = 42
Sex 145 F54 M 29 F13 M
Age at FU 43.8 ± 8.9 47.3 ± 9.8
Age at onset 27.2 ± 7.9 28 ± 8.8
Baseline EDSS 2.1 ± 0.9 3.17 ± 1.0
DD baseline years 7.8 ± 6.0 10.2 ± 7.5
DD FU years 16.9 ± 6.0 19.3 ± 8.0
AWM-f 1.0 ± 1.3 2.1 ± 2.5
CSF-f 14.2 ± 4.1 18.0 ± 5.8
GM-f 51.9 ± 2.8 49.4 ± 3.6
SRWL-IR 41.2 ± 11 34.7 ± 12.4
SRWL-DR 9 ± 3.3 9.7 ± 11
SRWL-REC 14.2 ± 3.1 14.6 ± 4.8
SDMT** -1.3 ± 1.5 -2 ± 1
PASAT** -1.1 ± 1.2 -2 ± 0.9
MCST-CAT 5.4 ± 1.9 4.7 ± 2.2
MCST-PE 4.4 ± 7 5.2 ± 6.2
MCST-NPE 5 ± 5.6 6.2 ± 6.9
*Adjusted for age, gender and education.
** z score.
doi:10.1371/journal.pone.0120754.t001
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Table 2. Univariable analysis verbal memory, sustained attention/information processing speed, executive function/conceptual reasoning.
VERBAL MEMORY SUSTAINED ATTENTION/
INFORMATION
PROCESSING SPEED
EXECUTIVE FUNCTION/CONCEPTUAL
REASONING
SRWL-IR
n = 230
SRWL-DR
n = 230
SRWL-REC
n = 228
SDMT
n = 222
PASAT
n = 217
MCST-CAT
n = 224
MCST-PE
n = 199
MCST-NPE
n = 199
Age OR 0.99,
p = 0.783
OR 1.00,
p = 0.896
OR 1.00,
p = 0.993
OR 1.04,
p = 0.008
OR 1.04,
p = 0.009
OR 1.02,
p = 0.318
OR 1.1,
p = 0.582
OR 1.04,
p = 0.059
CI 0.9–1.0 CI 1.0–1.1 CI 0.9–1.1 CI1.01–1.07 CI 1.01–1.07 CI 1.0–1.1 CI 1.0–1.1 CI 1.0–1.1
Age at
onset
OR 0.98
p = 0.234
OR 0.98,
p = 0.401
OR 0.99,
p = 0.901
OR 1.01,
p = 0.446
OR 1.02,
p = 0.164
OR 0.98,
p = 0.358
OR1.0
p = 0.82
OR 1.0
p = 0.814
CI 0.9–1.0 CI 0.9–1.0 CI 0.9–1.1 CI1.0–1.1 CI 1.0–1.1 CI 0.9–1.0 CI 0.9–1.0 CI 0.9–1.0
AWM-f OR 1.73
p<0.001
OR 1.63,
p<0.001
OR 1.27,
p = 0.523
OR 1.59,
p<0.001
OR 1.39,
p = 0.004
OR 1.50,
p<0.001
OR 1.48,
p = 0.001
OR 1.24,
p = 0.037
CI 1.4–2.2 CI 1.3–2.0 CI 0.6–2.6 CI1.2–2.1 CI 1.1–1.7 CI 1.2–1.8 CI 1.2–1.9 CI 1.01–1.52
CSF-f OR 1.15
p<0.001
OR 1.13,
p = 0.001
OR 1.11,
p = 0.329
OR 1.13,
p<0.001
OR 1.10,
p = 0.003
OR 1.11,
p = 0.001
OR 1.03,
p = 0.382
OR 1.06,
p = 0.087
CI 1.1–1.2 CI 1.1–1.2 CI 0.9–1.4 CI1.1–1.2 CI 1.03–1.18 CI 1.05–1.18 CI 1.0–1.1 CI 1.0–1.1
GM-f OR 0.8
p<0.001
OR 0.83,
p = 0.001
OR 0.94,
p = 0.638
OR 0.84,
p = 0.001
OR 0.88,
p = 0.007
OR 0.87,
p = 0.003
OR 0.94,
p = 0.22
OR 0.93,
p = 0.177
CI 0.7–0.9 CI 0.7–0.9 CI 0.7–1.2 CI0.8–0.9 CI 0.8–0.9 CI 0.8–0.96 CI 0.8–1.0 CI 0.8–1.0
GWM-f OR 0.9
p = 0.03
OR 0.89,
p = 0.057
OR 0.88,
p = 0.353
OR 0.95,
p = 0.219
OR 0.95,
p = 0.263
OR 0.90,
p = 0.032
OR 1.00,
p = 0.921
OR 0.95,
p = 0.365
CI 0.86–1.03 CI 0.8–1.0 CI 0.7–1.1 CI 0.9–1.0 CI 0.9–1.0 CI 0.83–0.99 CI 0.9–1.1 CI 0.9–1.1
WM-f OR 0.8
p<0.001
OR 0.85,
p<0.001
OR 0.89,
p = 0.309
OR 0.9,
p = 0.011
OR 0.9,
p = 0.032
OR 0.9,
p = 0.001
OR 0.9,
p = 0.122
OR 0.9,
p = 0.113
CI0.8–0.9 CI 0.8–0.9 CI 0.7–1.1 CI 0.84–0.98 CI 0.9–1.0 CI 0.8–0.9 CI 0.9–1.0 CI 0.9–1.0
Baseline OR 1.36
p = 0.072
OR 1.34,
p = 0.078
OR 1.17,
p = 0.695
OR 1.68,
p<0.001
OR 1.84,
p<0.001
OR 1.19,
p = 0.194
OR 1.1,
p = 0.546
OR 1.1,
p = 0.41
EDSS CI 1.0–1.9 CI 1.0–1.9 CI 0.5–2.5 CI 1.3–2.2 CI 1.4–2.5 CI 0.9–1.5 CI 0.8–1.5 CI 0.8–1.6
baseline OR 1.01
p = 0.334
OR 1.02,
p = 0.096
OR 1.04,
p = 0.222
OR 1.02,
p = 0.018
OR 1.02,
p = 0.031
OR 1.01,
p = 0.48
OR 1.0,
p = 0.733
OR 0.99,
p = 0.558
FSS CI 1.0–1.1
n = 221
CI 1.0–1.1
n = 228
CI 1.0–1.1
n = 226
C I1.004–1.04
n = 221
CI 1.002–1.04
n = 215
CI 1.0–1.1
n = 222
CI 0.9–1.0
n = 197
CI 0.9–1.0
n = 197
Disease OR 1.03
p = 0.242
OR 1.03,
p = 0.333
OR 1.03,
p = 0.628
OR 1.09,
p = 0.001
OR 1.05,
p = 0.04
OR 1.05,
p = 0.031
OR 1.01,
p = 0.606
OR 1.04,
p = 0.123
duration CI 1.0–1.1
n = 220
CI 1.0–1.1
n = 228
CI 0.3–1.2
n = 226
CI1.03–1.14
n = 220
CI 1.002–1.09
n = 215
CI 1.004–1.09
n = 222
CI 1.0–1.1
n = 197
CI 1.0–1.1
n = 197
progression OR 3.68
p = 0.001
OR 2.70,
p = 0.014
OR 0.49,
p = 0.4
OR 9.3,
p<0.001
OR 3.5,
p = 0.002
OR 1.7,
p = 0.134
OR 1.2,
p = 0.646
OR 1.5,
p = 0.321
CI 1.7–8.2 CI 1.2–6.0 CI 0.1–2.6 CI 3.1–27.3 CI 1.6–8.0 CI 0.9–3.4 CI 0.6–2.6 CI 0.7–3.3
gender OR 0.62
p = 0.290
OR 0.66,
p = 0.340
OR 0.50,
p = 0.369
OR 1.05,
p = 0.878
OR 1.1,
p = 0.743
OR 0.75,
p = 0.359
OR 1.01,
p = 0.968
OR 1.07,
p = 0.856
CI 0.3–1.5 CI 0.3–1.5 CI 0.1–2.3 CI 0.6–1.9 CI 0.6–2.0 CI 0.4–1.4 CI 0.5–2.0 CI 0.5–2.2
Δ EDSS OR 1.42
p = 0.002
OR 1.35,
p = 0.014
OR 1.32,
p = 0.357
OR 1.70,
p<0.001
OR 1.15,
p = 0.150
OR 1.21,
p = 0.057
OR 1.23,
p = 0.067
OR 1.03,
p = 0.832
CI 1.11–1.82 CI 1.06–1.71 CI 0.7–2.4
n = 226
CI 1.4–2.1
n = 220
CI 0.95–1.39 CI 0.9–1.5 CI 0.99–1.54 CI 0.8–1.3
Δ FSS OR 1.04
p = 0.003
OR 1.04,
p = 0.002
OR 1.04,
p = 0.137
OR 1.01,
p = 0.190
OR 1.00,
p = 0.716
OR 1.03,
p = 0.003
OR 1.03,
p = 0.015
OR 1.01,
p = 0.276
CI 1.01–1.06 CI 1.01–06.1
n = 225
CI 0.99–1.1
n = 223
CI 0.99–1.03
n = 218
CI 0.98–1.01
n = 214
CI 1.01–1.05
n = 219
CI 1.01–1.05
n = 194
CI 0.99–1.03
n = 194
doi:10.1371/journal.pone.0120754.t002
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14% RR!RR scores (p = 0.012). A multivariable analysis showed a positive correlation be-
tween SRWL-DR scores, AWM-f (OR 1.61 CI 1.28–2.03 p<0.001) and ΔFSS (OR 1.04 CI 1.01–
1.06 p = 0.004).In other words, for a 1% increase of AWM-f there was a 61% increased odds to
have SRWL-DR score under cut-off and ΔFSS was related to higher odds of impaired perfor-
mances at this test (see Table 3).
MCST scores of 224 patients were evaluated. Seventeen patients were excluded from the
analysis because their scores were not available. The MCST-category (CAT) scores of 49% of
RR!SP and 34% of RR!RR patients were under cut off (p = 0.08). The multivariable analysis
showed a positive correlation between MCST-CAT, AWM-f (OR 1.52, CI 1.2–1.9 p<0.001)
and ΔFSS (OR 1.03 CI 1.01–1.05 p = 0.004). In other words, a higher AWM-f was related to a
52% increased odds of MCST-CAT impairment and ΔFSS was related to higher odds of im-
paired performances at this test. Out of 199 RR!RR patients only 30% and 24% showed per-
severative (MCSTpe) and non perseverative errors (MCSTnpe) respectively. The multivariable
logistic regression step-wise model showed a positive correlation between AWM-f, MCSTpe
(OR 1.51 CI 1.2–1.9 p = 0.001) and ΔFSS (OR 1.03 CI 1.005–1.05 p = 0.016), such that a higher
AWM-f was related to a 51% increased odds to be cognitively impaired at this test and ΔFSS
was related to a higher odds of impaired performances at this test. Regarding MCSTnpe, a posi-
tive correlation was found with age (OR 1.04 CI 1.001–1.08 p = 0.048) and AWM-f (OR 1.26
CI 1.02–1.55 p = 0.032). This means that AWM-f was related to a 26% increased odds to be
cognitively impaired at MCSTnpe and one year increase in age was related to a 4% increased
odds of impaired performances at this test (see Table 3).
We evaluated cognitive performances of 227 patients. Out of them, 69 (28.6%) were cogni-
tively impaired and 158 (69.6%) cognitively preserved. In particular the prevalence of CIm was
27.1% in RR!RR and 45% in RR!SP group (p = 0.025). As expected, cognitively impaired pa-
tients showed a significantly higher overall CIm than cognitively preserved patients (19.0±3.8
Table 3. Multivariate analysis verbal memory, sustained attention/information processing speed, executive function/conceptual reasoning.
VERBAL MEMORY SUSTAINED ATTENTION/
INFORMATION PROCESSING
SPEED
EXECUTIVE FUNCTION/CONCEPTUAL REASONING
SRWL-IRn = 225 SRWL-DR
n = 225
SDMT n = 218 PASAT n = 217 MCST-CATn = 218 MCST-PEn = 194 MCST-NPE
n = 199
Age adjOR 1.04,
p = 0.004
adjOR 1.04,
p = 0.048
CI 1.01–1.08 CI 1.001–1.08
AWM-f adjOR1.72,
p<0.001
adjOR 1.61,
p<0.001
adjOR1.49,
p = 0.006
adjOR1.43,
p = 0.002
adjOR 1.52,
p<0.001
adjOR 1.51,
p = 0.001
adjOR 1.26,
p = 0.032
CI 1.35–2.20 CI 1.28–2.03 CI 1.12–1.97 CI 1.14–1.80 CI 1.2–1.9 CI 1.2–1.9 CI 1.02–1.55
Disease adjOR1.05,
p = 0.069
duration CI 0.996–1.11
ΔFSS adjOR 1.04
p = 0.006
adjOR 1.04
p = 0.004
adjOR
1.03p = 0.004
adjOR 1.03,
p = 0.016
CI 1.01–1.06 CI 1.01–1.06 CI 1.01–1.05 CI 1.005–1.05
Baseline
EDSS
adjOR1.66,
p = 0.003
CI 1.19–2.32
Δ EDSS adjOR1.73,
p<0.001
CI 1.4–2.2
doi:10.1371/journal.pone.0120754.t003
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and 10.8±3.9, p<0.001). The multivariable logistic regression step-wise model regarding CIm
showed a positive correlation with AWM-f (OR 1.63, CI 1.3–2.1, p>0.001) and disease dura-
tion (OR 1.04, CI 1.0–1.1, p = 0.06). A negative binomial regression analysis showed AWM-f
was the only significant parameter showing an Incidence Rate Ratio of 1.09 (CI 1.06–1.12,
p>0.001). In other words for a 1% increase of AWM-f there was a 9% increased overall CIm
index score. Considering EDSS at baseline and FU visit we found median EDSS was 2.0 at BL
and 3.0 at the end of FU (p< 0.001). Logistic regression showed a positive correlation between
ΔEDSS and CIm (OR 1.29 CI 95% 1.05–1.57 p = 0.013): this means that one point increase in
EDSS was related to 29% odds to be cognitively impaired. Considering FSS at baseline and FU,
we found median FSS was 26 at BL and 37 at FU (p<0.001). Logistic regression showed a posi-
tive correlation between ΔFSS and CIm (OR 1.03 CI 95% 1.01–1.05 p = 0.004), such that one
point increase of FSS was related to 3% odds to be cognitively impaired. Moreover, the multi-
variable analysis showed a positive correlation between ΔEDSS and SDMT (OR 1.73 p<0.001),
and between ΔFSS, and SRWL-IR (OR 1.04 p = 0.006), SRWL-DR (OR 1.04 p = 0.004),
MCSTCAT (OR 1.03 p = 0.004) and MCST-pe (OR 1.03 p = 0.01).
Discussion
In this study we evaluated the role of WM, GM and LL (i.e. AWM-f) volumes in predicting the
long-term occurrence of CIm in a large group of MS patients.
In the last years, it has been showed that CIm is more related to brain atrophy than to LL in
mildly disabled MS patients [4, 8]. On the other hand, WM lesions seem to play an important
role in the development of CIm as well [20, 21]. The contribution of WM damage to CIm is
also confirmed by studies reporting a clear association between cognitive functioning and cor-
tico–cortical and cortico–subcortical WM tracts damage [21, 22]. In particular, the association
between the WM damage and the impairment of information processing speed, generally stud-
ied by PASAT and SDMT, is frequently demonstrated [23]. A 5 years-follow up study showed
that brain atrophy is a good predictor of cognitive functioning in RRMS patients, although also
T1-hypointense lesions showed a good predictive value [5]. This is in line with findings sug-
gesting that atrophy of cortical and sub-cortical deep GM could be associated with WM lesion
burden [24]. However, the pathophysiologic process remains poorly understood [25].
Using a fully automated segmentation method, we found that AWM-f, indicating LL, was
the best predictor of CIm in MS patients. In particular, AWM-f was predictive of an impaired
SDMT performance. The lower SDMT scores in RR!SP patients compared to RR!RR (pro-
portion of RRMS and SPMS patients with impaired performance at each test represented in
Fig. 2) and the positive correlation with EDSS at BL, underline the influence of accrual of dis-
ability andWM damage on cognitive performance. Since an interaction between motor disabil-
ity and cognition has been demonstrated, especially on progressive patients, we cannot exclude
that motor impairment may affect in part CIm [26]. However, our patients have a relatively
mild disability, being baseline EDSS below 4 for both RRMS and SPMS (2.1 ± 0.9 and 3.17 ± 1
respectively). Our results showed higher PASAT scores in RR!RR if compared to RR!SP pa-
tients. In the multivariable analysis, age and AWM-f were the only variables predictive of lower
PASAT scores, confirming previous findings showing that lower age was related to better per-
formances at this test [27].Taken together, these results underline the importance of WM tract
integrity in the rapid transfer of information between the cortex and deep GM, suggesting the
involvement of WM in processing speed deficits.
Regarding MCST, we found a positive correlation with AWM-f. This is in line with other
studies, showing that although MCST has a lower sensitivity than other executive function
tests in MS, it is strongly correlated with brain atrophy and LL [28].
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RR!SP showed lower SRWL scores when compared to RR!RR group. Moreover, we
found a positive correlation between AWM-f and the incidence of being classified as impaired
on the SRWL.
Our results could be apparently in contrast with other studies reporting that patients with pro-
gressive MS show deficits in information processing speed, attention, working memory, executive
function, and verbal episodic memory, whereas CIm of RRMS patients is limited to information
processing speed and working memory [29]. The association between verbal memory and GM
pathology is frequently reported. Using a different battery (BRB) and a different MRI technique,
Amato et al [30] showed a clear association between GM atrophy and verbal memory, suggesting
the involvement of cortical regions in the neuropathological process at the early stage of the dis-
ease; however, given the cross sectional nature of the study, a direct comparison with the results
presented herein is not possible. Memory deficits of MS patients were initially thought to be due
only to impaired retrieval. More recent explanations postulate that verbal memory impairment is
the consequence of an inadequate acquisition and retrieval, both secondary to information pro-
cessing insufficiency [31], although it is conceivable the impairment of memory and information
processing speed may result from the same pathological process. In line with this perspective, a
robust correlation between CIm and LL is reported in a number of studies conducted with mildly
disabled patients or at the early stage of the disease [32–34] Using high field MRI, a correlation
between Normal AppearingWM, SDMT and CVLT-II [35] scores has been demonstrated,
Fig 2. Proportion of RRMS and SPMS patients with impaired performance at each test. Legend: RRMS = relapsing-remitting multiple sclerosis,
SPMS = secondary progressive multiple sclerosis, SDMT = symbol digit modality test, PASAT-3 = 3.0 inter-stimulus interval of Paced Auditory Serial
Addition Test, SRWL = semantically related word list test, IR = immediate recall, DR = delayed recall, REC = recognition, MCST CAT = modified card sorting
test categories, MCST-PE = MCST perseverative errors, MCST-NPE = MCST non-perseverative errors.
doi:10.1371/journal.pone.0120754.g002
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highlighting the crucial role of WM tract integrity in verbal learning, ensuring rapid transfer of
information between cortex and deep GM. In our study, we support the role of a fully automated,
operator-independent, multiparametric segmentation method to measure AWM-f, as marker of
LL and bothWM and GM volumes [10].MRI was performed 9 years before the NPS, which al-
lows us to suppose that AWM-f could be considered an early predictor of CIm, strengthening the
concept of a possible involvement ofWM in the development of CIm. It is conceivable that CIm
in our patients is, at least in part, caused by central neural pathways-disconnection. A “discon-
nection model” could interpret the involvement of multiple cognitive domains in this pathology
as a series of disconnection syndromes affecting different cognitive networks. We propose that
disruption of cortical WM tracts leads to reduced connectivity between cortico-cortical and cor-
tico-subcortical cognitive processing regions, resulting in deficits in specific cognitive domains.
On the other hand, this kind of model does not exclude GM pathology [3, 30] which may play a
more important role as the disease progress [36]. Recently, a 13-year follow-up study showed
that GMmagnetization transfer ratio (MTR) was the only MRI predictor of global CIm, support-
ing the notion that GM plays a major role in the long-term development of CIm [37]. However,
we cannot rule out that GM damage is secondary toWM damage, emphasizing the role of WM
as an early marker of CIm.
Our study has the appeal of focusing on the long term predicting value of MRI parameters
in a real life setting of MS management, being our cohort not in the early phase of the disease
and having a relatively low disability.
However, our project has several limitations. First, though we had the great advantage to
use the same (mobile) scanner in each participating center so that all patients shared the same
protocol on the same scanner, we used a 1.0 Tesla MRI scanner which did not allow us to per-
form more advanced MRI measurements (i.e. WM tractography). Second, we did not have a
baseline cognitive evaluation, therefore we could not assess the cognitive profile of patients at
such time-point. Third we did not perform a FUMRI to assess the longitudinal change in
brain volume. On the other hand, the use of an accurate and automatic segmentation method
gave us the advantage to simultaneously assess LL, WM and GM volumes in a large population
of patients and in a time-saving fashion. Finally, we did not use a universally accepted method
to calculate the overall CIm, thus possibly underestimating the real burden of CIm. Since there
is a lack of a standardized classification criteria, we used two different strategies to have an esti-
mate of global CIm: a composite index score based on a graded system [19] and a domain spe-
cific CIm. Furthermore, since the number of test may influence cognitive outcome, we decided
to use a brief NPS evaluation, investigating the most commonly affected cognitive domains in
MS, giving us the opportunity to test a large number of patients [38].Although we used a brief
NPS battery, not all patients completed tests. However, given the small number of missing data
for every test (19 were excluded from SDMT analysis, 24 from PASAT analysis, 11 from SRWL
analysis, 17 from MCST) we do not believe this may affect our results.
In conclusion, our findings suggest that WMLL, a reliable and relatively easy to acquire
MRI parameter, may have a role in the pathology of CIm in MS patients and could be consid-
ered as an early predictor of future cognitive decline. Further longitudinal studies are needed to
better clarify the relation between WMLL and GM damage. In particular, we suggest that the
use of automated segmentation procedures might be useful for planning future studies focused
on selecting the best parameters for monitoring cognitive decline in MS patients.
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